Draznin B
Department of Medicine, University of Colorado, Health Sciences Center, Denver.
Am J Kidney Dis. 1993 Jun;21(6 Suppl 3):32-8. doi: 10.1016/0272-6386(93)70122-f.
The presence of insulin resistance in many patients with hypertension has become a well-recognized phenomenon. However, the mechanism of this association remains enigmatic. We have hypothesized that abnormal cellular calcium handling, particularly elevations in cytosolic free calcium concentrations, may represent a common intracellular abnormality (a missing link) that is responsible for the frequent co-existence of insulin resistance and hypertension. We have shown recently that sustained elevations of cytosolic free calcium in insulin target cells, such as are observed in patients with obesity and non-insulin-dependent diabetes mellitus and in some patients with hypertension, may lead to the development of insulin resistance. Although the mechanisms that lead to such increases are not yet well understood, they appear to include an enhanced influx of calcium via calcium channels. We found that the presence of the calcium antagonist nitrendipine in the incubation medium prevented increases in cytosolic free calcium concentration and ameliorated the insulin resistance induced by various mechanisms. To further evaluate the existence of an association between elevated levels of cytosolic calcium and diminished cellular sensitivity to insulin in patients with essential hypertension, we studied insulin sensitivity in vivo and in vitro in isolated adipocytes from older hypertensive, nondiabetic subjects. Obese hypertensive individuals demonstrated marked hyperinsulinemia and significantly reduced submaximally stimulated adipocyte 2-deoxyglucose uptake. One month of therapy with nitrendipine (10 mg twice daily) reduced blood pressure in hypertensive subjects, reduced plasma insulin to control values in obese hypertensive individuals, and restored adipocyte 2-deoxyglucose uptake at at submaximally effective insulin concentrations to control values in both obese hypertensive subjects and those of normal weight.(ABSTRACT TRUNCATED AT 250 WORDS)
许多高血压患者存在胰岛素抵抗,这已成为一个公认的现象。然而,这种关联的机制仍然不明。我们推测,细胞钙处理异常,尤其是胞质游离钙浓度升高,可能代表一种常见的细胞内异常(缺失环节),它导致胰岛素抵抗和高血压经常并存。我们最近发现,在胰岛素靶细胞中持续升高的胞质游离钙,如在肥胖和非胰岛素依赖型糖尿病患者以及一些高血压患者中所观察到的,可能导致胰岛素抵抗的发生。尽管导致这种升高的机制尚未完全清楚,但似乎包括通过钙通道增强的钙内流。我们发现,孵育培养基中存在钙拮抗剂尼群地平可防止胞质游离钙浓度升高,并改善各种机制诱导的胰岛素抵抗。为了进一步评估原发性高血压患者胞质钙水平升高与细胞对胰岛素敏感性降低之间是否存在关联,我们在老年高血压非糖尿病受试者分离的脂肪细胞中进行了体内和体外胰岛素敏感性研究。肥胖高血压个体表现出明显的高胰岛素血症,亚最大刺激的脂肪细胞2-脱氧葡萄糖摄取显著降低。尼群地平(每日两次,每次10毫克)治疗一个月可降低高血压受试者的血压,使肥胖高血压个体的血浆胰岛素降至对照值,并使肥胖高血压受试者和正常体重受试者在亚最大有效胰岛素浓度下的脂肪细胞2-脱氧葡萄糖摄取恢复至对照值。(摘要截短于250字)